Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer

American Journal of Epidemiology

Volumn 175, Issue 7, 2012, Pages 685-695

  Andersson, Kristin ^a   Michael, Kristina M ^b   Luostarinen, Tapio ^c   Waterboer, Tim ^b   Gislefoss, Randi ^d   Hakulinen, Timo ^c   Forslund, Ola ^a   Pawlita, Michael ^b   Dillner, Joakim ^a,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c FINNISH CANCER REGISTRY   (Finland)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

papillomavirus; DNA tumor viruses; Human papillomavirus

Indexed keywords

VIRUS ANTIBODY;

ANTIBODY; CANCER; DISEASE INCIDENCE; HEALTH RISK; HYPOTHESIS TESTING; RISK FACTOR; SERUM; SKIN DISORDER; SPATIOTEMPORAL ANALYSIS; VIRAL DISEASE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; FEMALE; GENUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PROSPECTIVE STUDY; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; SWEDEN; VIRUS CARCINOGENESIS; VIRUS TYPING; WART VIRUS;

ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NORWAY; ODDS RATIO; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; REGISTRIES; RISK; RISK FACTORS; SEX FACTORS; SKIN NEOPLASMS; SWEDEN;

NORWAY; SWEDEN;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84859486629     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr373     Document Type: Article

References (32)

1. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324(1):17-27. (Pubitemid 38737395)
2. de Koning MN, Weissenborn SJ, Abeni D, et al. Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol. 2009;90(7):1611-1621.
3. Waterboer T, Neale R, Michael KM, et al. Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia. J Gen Virol. 2009;90(8):1986-1998.
4. Astori G, Lavergne D, Benton C, et al. Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol. 1998;110(5):752-755. (Pubitemid 28194022)
5. Forslund O, Iftner T, Andersson K, et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis. 2007;196(6):876-883. (Pubitemid 47378937)
6. Patel AS, Karagas MR, Perry AE, et al. Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study. J Invest Dermatol. 2008;128(12):2888-2893.
7. Struijk L, Hall L, van der Meijden E, et al. Markers of cutaneous human papillomavirus infection in individuals with tumor-free skin, actinic keratoses, and squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(3):529-535.
8. Asgari MM, Kiviat NB, Critchlow CW, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol. 2008;128(6):1409-1417. (Pubitemid 351693210)
9. Waterboer T, Abeni D, Sampogna F, et al. Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. Br J Dermatol. 2008;159(2):457-459. (Pubitemid 352009826)
10. Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst. 2006;98(6):389-395.
11. Andersson K, Waterboer T, Kirnbauer R, et al. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev. 2008;17(1):189-195. (Pubitemid 351196290)
12. Feltkamp MC, Broer R, di Summa FM, et al. Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res. 2003;63(10):2695-2700. (Pubitemid 36605215)
13. Forslund O, Lindelöf B, Hradil E, et al. High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "stripped" biopsies from the same tumors. J Invest Dermatol. 2004;123(2):388-394. (Pubitemid 38951835)
14. Weissenborn SJ, Neale R, de Koning MN, et al. Prevalence and multiplicity of cutaneous beta papilloma viruses in plucked hairs depend on cellular DNA input. J Virol Methods. 2009;161(2):280-283.
15. Plasmeijer EI, Neale RE, de Koning MN, et al. Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma. Cancer Res. 2009;69(23):8926-8931.
16. Bouwes Bavinck JN, Plasmeijer EI, Feltkamp MC. Beta-papillomavirus infection and skin cancer. J Invest Dermatol. 2008;128(6):1355-1358.
17. Akgül B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol. 2006;208(2):165-175. (Pubitemid 43126110)
18. Casabonne D, Michael KM, Waterboer T, et al. A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121(8):1862-1868. (Pubitemid 47417308)
19. Kullander J, Forslund O, Dillner J. Staphylococcus aureus and squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 2009;18(2):472-478.
20. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol. 1999;9(6):423-430. (Pubitemid 30184512)
21. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem. 2005;51(10): 1845-1853. (Pubitemid 41368175)
22. Pukkala E, Andersen A, Berglund G, et al. Nordic biological specimen banks as basis for studies of cancer causes and control - more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol. 2007;46(3):286-307. (Pubitemid 46625036)
23. Langseth H, Giselfoss R, Martinsen JI, et al. The Janus Serum Bank - From Sample Collection to Cancer Research. Oslo, Norway: Cancer Registry of Norway. 2009.
24. Larsen IK, Sma° stuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218-1231.
25. Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods. 2001;253(1-2):153-162. (Pubitemid 32522523)
26. Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods. 2006;309(1-2):200-204. (Pubitemid 43190816)
27. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
28. Favre M, Majewski S, Noszczyk B, et al. Antibodies to human papillomavirus type 5 are generated in epidermal repair processes. J Invest Dermatol. 2000;114(3):403-407. (Pubitemid 30415323)
29. Vasiljević N, Nielsen L, Doherty G, et al. Differences in transcriptional activity of cutaneous human papillomaviruses. Virus Res. 2008;137(2):213-219.
30. Schaper ID, Marcuzzi GP, Weissenborn SJ, et al. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res. 2005;65(4):1394-1400. (Pubitemid 40270167)
31. Cordano P, Gillan V, Bratlie S, et al. The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology. 2008;377(2): 408-418.
32. Dong W, Arpin C, Accardi R, et al. Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints. Oncogene. 2008;27(20):2923-2928. (Pubitemid 351620445)